PolackFPThomasSJKitchinN, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng J Med. 2020;383:2603-2615. doi:10.1056/NEJMoa2034577
2.
ChodickGTeneLRotemRS, et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2022;74:472-478. doi:10.1093/cid/ciab438
LiJJiaHTianM, et al. SARS-CoV-2 and emerging variants: unmasking structure, function, infection, and immune escape mechanisms. Front Cell Infect Microbiol. 2022;12:869832. doi:10.3389/fcimb.2022.869832
5.
DayamRMLawJCGoetgebuerRL, et al. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. JCI Insight. 2022;7:e159721. doi:10.1172/jci.insight.159721
6.
ZhangJJDongXLiuGHGaoYD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023;64:90-107. doi:10.1007/s12016-022-08921-5
7.
PapagorasCFragoulisGEZiogaN, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81:1013-1016. doi:10.1136/annrheumdis-2021-221539
8.
ShenCRiskMSchiopuE, et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann Rheum Dis. 2022;81(6):875-880. doi:10.1136/annrheumdis-2021-222045
9.
BieberASagyINovackL, et al. BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study. Ann Rheum Dis. 2022;81:1028-1035. doi:10.1136/annrheumdis-2021-221824
